Starting March 1, 2020, ConnectiCare will review preauthorization requests that providers previously submitted to our partner, Magellan Rx Management (Magellan Rx), for our Medicare Advantage members.
These preauthorization requests involve the following specialty drugs:
- Intravenous Immunoglobulin (IVIG)
- Subcutaneous Immunoglobin (SCIG)
- Remicade® (infliximab)
- All Remicade’s biosimilar products
This is related to the news we shared with you last month regarding our commercial members.
You can request authorizations for the above specialty drugs from ConnectiCare by:
|Commercial patients||Medicare Advantage patients|